LNTH TD Cowen 45th Annual… Presentation

Page 1

Lantheus Investor Presentation Building on our Foundation to Power the Future of Radiopharmaceuticals TD Cowen 45th Annual Health Care Conference March 4, 2025 © 2025 Lantheus. All rights reserved. NASDAQ: LNTH

Page 2

Safe Harbor Statements Cautionary Statement Regarding Forward-Looking Statements This document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, that are subject to risks and uncertainties and are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may be identified by their use of terms such as “advance,” “anticipated,” “assumes,” “believes,” “building,” “commitment,” “continue,” “could,” “deliver,” “drive,” “expand/expansion,” “expected,” “growth,” “guidance,” “increasing,” "intend", “launching,” “long-term,” “may,” “milestone,” “opportunity,” “pipeline,” “plan,” “position,” “potential,” “predict,” “should,” “subject to,” “sustained/sustainable,” “target,” “will,” and other similar terms. Such forward- looking statements include our guidance for the fiscal year 2025, our plans to expand our portfolio of late-stage assets and high potential early-stage candidates, our potential acquisitions of Life Molecular Imaging Ltd., (“Life Molecular”) and Evergreen Theragnostics Inc. (“Evergreen”), and our expectations relating to adding a commercial team in the Alzheimer’s space and a CDMO business from the Life Molecular acquisition, and are based upon current plans, estimates and expectations that are subject to risks and uncertainties that could cause actual results to materially differ from those described in the forward-looking statements. The inclusion of forward-looking statements should not be regarded as a representation that such plans, estimates and expectations will be achieved. Readers are cautioned not to place undue reliance on the forward-looking statements contained herein, which speak only as of the date hereof. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law. Risks and uncertainties that could cause our actual results to materially differ from those described in the forward-looking statements include: (i) continued market expansion and penetration for our established commercial products, particularly PYLARIFY and DEFINITY, in a competitive environment, and our ability to clinically and commercially differentiate our products; (ii) our ability to have third parties manufacture our products and our ability to manufacture DEFINITY in our in-house manufacturing facility, in the amounts and at the times needed; (iii) availability of raw materials, key components, and equipment, either used in the production of our products and product candidates, or in the use by HCPs of our products and product candidates, including, but not limited to PET scanners used for PYLARIFY, MK-6240 and NAV-4694; (iv) our ability to satisfy our obligations under our existing clinical development partnerships using MK-6240 or NAV-4694 as a research tool and under the license agreements through which we have rights to MK-6240 and NAV-4694, and to further develop and commercialize MK-6240 and NAV-4694 as approved products, including the timing for any potential regulatory submissions for these investigational assets; (v) our ability to successfully secure necessary shareholder and regulatory approvals relating to potential acquisitions, including of Life Molecular and Evergreen, the time and expense involved in seeking to secure those approvals, potential disruption to our business operations or those of the companies we plan to acquire while the acquisitions are pending or as a result of regulatory requirements related to the acquisitions; potential disruption to operations and productivity during the integration process after necessary approvals are secured and the potential that we are unable to integrate and realize the anticipated benefits that each acquisition is predicted to bring; (vi) our strategies, future prospects, and our projected growth, including revenue related to our collaboration agreements with POINT Biopharma Global Inc., including our ability to obtain U.S. Food and Drug Administration (“FDA”) approval for PNT2002 and PNT2003 and to be successful in the patent litigation associated with PNT2003; (vii) the cost, efforts and timing for clinical development, regulatory approval, adequate coding, coverage and payment and successful commercialization of our product candidates and new clinical applications and territories for our products, in each case, that we or our strategic partners may undertake; (viii) our ability to identify opportunities to collaborate with strategic partners and to acquire or in-license additional diagnostic and therapeutic product opportunities in oncology, neurology and other strategic areas and continue to grow and advance our pipeline of products.; and (ix) the risk and uncertainties discussed in our filings with the Securities and Exchange Commission (including those described in the Risk Factors section in our Annual Reports on Form 10-K and our Quarterly Reports on Form 10-Q). All trademarks, logos and service marks used in this presentation are the property of their respective owners. Non-GAAP Financial Measures The Company uses non-GAAP financial measures, such as adjusted net income and its line components; adjusted net income per share - fully diluted; adjusted operating income and free cash flow. The Company’s management believes that the presentation of these measures provides useful information to investors. These measures may assist investors in evaluating the Company’s operations, period over period. However, these measures may exclude items that may be highly variable, difficult to predict and of a size that could have a substantial impact on the Company’s reported results of operations for a particular period. Management uses these and other non-GAAP measures internally for evaluation of the performance of the business, including the allocation of resources and the evaluation of results relative to employee performance compensation targets. Investors should consider these non-GAAP measures only as a supplement to, not as a substitute for or as superior to, measures of financial performance prepared in accordance with GAAP. © 2025 Lantheus. All rights reserved. 2

Page 3

© 2025 Lantheus. All rights reserved. Lantheus is the leading radiopharmaceutical-focused company and is committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes. 3 FIND. FIGHT. FOLLOW. ®

Page 4

4 Lantheus: Setting the Stage for Sustained, Double-Digit Growth © 2025 Lantheus. All rights reserved. • Adds OCTEVY, a registrational-stage PET radiodiagnostic, complementary to PNT2003 • Establishes clinical and commercial radiopharmaceutical manufacturing • Enhances early R&D capabilities • Adds Neuraceq, an approved PET radiodiagnostic, and commercial franchise • Enhances R&D and clinical development capabilities Key Recent Strategic Announcements* Key Drivers 2026-2027 Anticipated Product Launches *Acquisitions subject to customary closing conditions and anticipated to close 2H 2025 1 2 3 Pipeline LNTH-1363S Cu64 FAP-targeted radiodiagnostic LNTH-2401 RM2, GRPR-targeted radiodiagnostic LNTH-2402 RM2, GRPR-targeted radiotherapeutic LNTH-2403 LRRC15-targeted radiotherapeutic LNTH-2404 TROP2-targeted radiotherapeutic MK-6240 F18 tau-targeted PET radiodiagnostic NAV-4694 F18 β amyloid-targeted PET radiodiagnostic OCTEVY* F18 GEP-NET PET radiodiagnostic PNT2003 SSTR+ GEP-NET radioequivalent *

Page 5

5 Continued Strong Financial Performance1 1. See slides 34 and 35 for a reconciliation of GAAP to non-GAAP financials; certain amounts may be subject to rounding. 2. Guidance provided on February 26, 2025. On a forward-looking basis, the Company does not provide GAAP income per common share guidance or net cash provided by operating activities guidance or a reconciliation of GAAP income per common sha re to adjusted fully diluted EPS or net cash provided by operating activities to free cash flow because the Company is unable to predict with reasonable certainty business development and acquisition- related expenses, purchase accounting fair value adjustments and any one -time, non-recurring charges, or the net effect of non-cash items. These items are uncertain, depend on various factors, and could be material to results computed in accordance with GAAP. As a resul t, it is the Company’s view that a quantitative reconciliation of adjusted fully diluted EPS and free cash flow on a forward-looking basis is not available without unreasonable effort.3. FY 2025 guidance assumes fully diluted, weighted avg. shar es outstanding of approximately 71.5M YTD, and depreciation and amortization of ~$56M. 4. Cash, cash equivalents and restricted cash at the end of the period was $914.5 M. As of December 31, 2024 $912.8M Cash on Hand4 $750M Available Revolving Credit $339 $425 $935 $1,296 $1,534 2020 2021 2022 2023 2024 Annual Revenue ($ Millions) $0.47 $0.49 $4.22 $6.23 $6.76 2020 2021 2022 2023 2024 Annual Adj. EPS $4 $42 $263 $259 $493 2020 2021 2022 2023 2024 Annual Free Cash Flow ($ Millions) FY 2025 Revenue $1.545B – $1.610B Adjusted Fully Diluted EPS3 $7.00 – $7.20 The Company guidance for the full year 2025 is as follows2: Free Cash Flow to continue to expand throughout 2025 with an anticipated amount of $550M - $600M

Page 6

Lantheus’ Journey has Driven Growth and Success Over 65 Years © 2025 Lantheus. All rights reserved. 6 FDA APPROVAL & CLEARANCE CORPORATE GROWTH 2020 Lantheus Holdings closes merger with Progenics Pharmaceuticals 2015 IPO on Nasdaq 2008 BMS sells BMS Medical Imaging to Avista Capital Partners, Lantheus Medical Imaging launched 2001 Bristol Myers Squibb Co. purchases DuPont Pharmaceuticals 1998 DuPont buys Merck’s interest, becomes DuPont Pharmaceuticals 1991 DuPont forms venture with Merck called DuPont Merck 1981 DuPont purchases NEN 1956 Founded 2023 Acquires Cerveau Technologies – including MK-6240, novel PET imaging agent for Alzheimer’s Disease 2022 In-licenses PNT2002 and PNT2003 – two late-stage radiotherapeutic product candidates 2025 Announces plans to acquire Evergreen Theragnostics and Life Molecular Imaging 2024 Expands pipeline with three strategic transactions 1976 FDA Approval 1990 FDA Approval 2001 FDA Approval 1974 FDA Approval 1994 FDA Approval FDA Clearance 2021 FDA Approval 2024 FDA Approval Strategic investments in 2023 EMA Approval Out licensed to Curium Out licensed to GE Healthcare

Page 7

Lantheus’ Journey has Driven Growth and Success Over 65 Years © 2025 Lantheus. All rights reserved. 7 2020 Lantheus Holdings closes merger with Progenics Pharmaceuticals 2023 Acquires Cerveau Technologies – including MK-6240, novel PET imaging agent for Alzheimer’s Disease 2025 Announces plans to acquire Evergreen Theragnostics and Life Molecular Imaging FDA Clearance 2021 FDA Approval 2023 EMA Approval Out licensed to Curium 2024 FDA Approval Out licensed to GE Healthcare 2022 In-licenses PNT2002 and PNT2003 – two late-stage radiotherapeutic product candidates 2024 Acquires Meilleur Technologies – including NAV-4694 Acquires LRRC15 and TROP2 from Strategic investments in FDA APPROVAL & CLEARANCE CORPORATE GROWTH

Page 8

Page 9

© 2025 Lantheus. All rights reserved. 99 1. Internal analyses and data on file. 9 FY 2024 4Q 2024 $1.1B FY 2024 Net Sales +24.3% Growth FY 2024 Year-over-Year $266.0M 4Q 2024 Net Sales +15.7% Growth 4Q 2024 Year-over-Year 2025 Revenue Expectation Year-over-Year Low to Mid-Single Digit Growth First Radiodiagnostic to Achieve BLOCKBUSTER STATUS 0 200 400 600 800 1000 1200 2021 2022 2023 2024 PYLARIFY Sales Year-over-Year Utilized PSMA PET Imaging Agent1 $43M $527M $851M $1.058B

Page 10

10 PYLARIFY Offers Clear Clinical Value to Patients and Healthcare Providers *Change in intended prostate cancer treatment plan was a secondary endpoint in CONDOR. Future studies ll be necessary to demonstrate whether PYLARIFY® PET/CT-directed changed in intended patient management lead to improved outcomes for patients with prostate cancer.1 1. Data on file, Lantheus. 2. PYLARIFY® [package insert]. North Billerica, MA: Progenics Pharmaceuticals, Inc., a Lantheus company. 3. Morris MJ, Rowe SP, Gorin MA, et al. Diagnostic performance of 18F-DCFPyL-PET/CT in men with biochemically recurrent prostate cancer: results from the CONDOR phase III, multicenter study. Clin Cancer Res. 2021 July 01;27(13):3674-3682. doi:10.1158/1078-0432.CCR-20-4573 © 2025 Lantheus. All rights reserved. PYLARIFY’s change in intended patient management is based on 99% of enrolled patients in our CONDOR study In PYLARIFY’s Phase 3 pivotal study, nearly two out of three patients in the study with BCR who received PYLARIFY® after negative or uninformative conventional imaging had a change in intended PC treatment Note: It is not known if changes in intended patient management lead to improved outcomes for patients 99% Study Design CONDOR was a multicenter, phase 3 trial of 208 patients with suspected recurrent or metastatic prostate cancer with negative or equivocal results using standard imaging. The primary endpoint was CLR; the key secondary endpoint was the percentage of patients with a change in intended PC treatment plan. CLR is a measure of positive predictive value enhanced with precise anatomic location of the site of disease. CLR is based on anatomic lesion matching, or co-localization, of lesions identified by PYLARIFY® (piflufolastat F 18) injection and lesions identified by the standard of truth.3* Change in Intended Patient Management1-3 Courtesy (with permission) from Gary Ulaner, MD, PhD, FACNM, Hoag Family Cancer Institute

Page 11

© 2025 Lantheus. All rights reserved. 11 Patient Treatment Logistics Require Real-Time Delivery of Doses F18 is produced on a cyclotron PYLARIFY is manufactured and formulated in a synthesis box Finished as a bulk vial Robust quality control and testing Drawn into patient-ready doses PYLARIFY patient- ready doses “out the door” 110-minute half-life advantage Easily transported any time of day within a ~3-hour radius Patient is injected and scanned PYLARIFY Synthesis, Distribution and Utilization PYLARIFY Batch Manufacturing Process Can Produce Ample Supply to Meet the Needs of this Sizeable Patient Population

Page 12

12 PYLARIFY is widely available through a diverse, multi-partner F18 distributor supply network, ensuring convenient and reliable supply PR PMF Capacity, Coverage and Dose Availability Varies from Site to Site *Data as of January 1, 2025 NOTE: Markers represent epicenter of PMF site market range/coverage © 2025 Lantheus. All rights reserved. Extensive manufacturing network* with multiple radiopharmacies serving imaging centers in 48 states, District of Columbia, and Puerto Rico 1 Coverage and reliability within and between radiopharmacies, with an increasing number of cyclotrons to expand capacity and extend calibration windows Commitment to continued expansion and excellent customer service with enhancements to the online ordering platform offering added flexibility 1. Data on file, Lantheus.

Page 13

© 2025 Lantheus. All rights reserved. 13 U.S. PSMA PET Imaging Market Potential of $3.5B+ by 2030 1. Market research interviews, survey, and analysis, Wenzel 2021 Prostate, Nezolosky 2018 J. Clin. Oncol., Agrawal 2020 JAMA. 2. Scher HI, Solo K, Valant J, Todd MB, Mehra M. 2015. Prevalence of Prostate Cancer Clinical States and Mortality in the United States: Estimates Using a Dynamic Progression Model. PloS one 10: e0139440. Based on: CDC.gov, SEER Database, NCCN.org and Axiom Primary and Secondary Market Research and Analysis, validated by Bohm Epidemiology 2020. 3. Expanded RLT indication from 3L only to 1L, 2L & mHSPC (metastatic Hormone Sensitive Prostate Cancer). 4. Addressable market based on current management estimates, internal data and current WAC / 340B pricing. ~525K ANNUAL SCANS $2.5B+ MARKET POTENTIAL4 750K+ ANNUAL SCANS $3.5B+ MARKET POTENTIAL4 INITIAL STAGING FOR SUSPECTED METASTASES1 PSMA-TARGETED RADIOLIGAND THERAPY3 SUSPECTED RECURRENCE2 350,000 145,000 30,000 2025 200,000 375,000 175,000 2030 Annual Market and Scan Potential Factors Influencing Market Expansion: Expansion of Radiotherapeutics into earlier lines of treatment (i.e., from 3L mCRPC to include 2L, 1L and mHSPC populations) Increasing clinical utility of PSMA PET imaging in BCR population (increased number of scans per patient) Expansion of Initial Staging population to include patients with an Intermediate Favorable risk profile Overall increase in epidemiological population, 2-3% per year

Page 14

© 2025 Lantheus. All rights reserved. 14 Strategic Plan Phase 4 n = 274 PYLARIFY MIRROR Study: Phase 4 Study in Favorable Intermediate Risk (FIR) Prostate Cancer Population: Newly diagnosed Favorable Intermediate Risk Prostate Cancer confirmed by standard of care Day -30 to Day 1 Screening and baseline procedures Pre-PYLARIFY Intended Clin Management questionnaire Dosing of PYLARIFY at 9mCi t=0 Whole body PET/CT PET or MRI scan t=1-2 hours AE assessment Day 1 Post- PYLARIFY Intended Clin Management questionnaire By Day 30 Subjects scheduled for R/P with PLND: • Local histology +/– • Confirmatory imaging Subjects NOT scheduled for R/P with ≥1 lesion(s) on PYLARIFY PET: • Verification of suspected lesion(s): confirmatory imaging and/or biopsy By Day 90 All subjects: • PSA monitoring • Post-PYLARIFY medical management questionnaire at 6 and 12 months • Collect standard of care imaging and/or local histopathology as clinically indicated Patient follow-up for 12 months post-PYLARIFY dosing Primary Endpoint Detection rate of intraprostatic ISUP grade ≥3 lesion(s) as confirmed by pathology; or the presence of extra-prostatic extension, seminal vesicle invasion, regional lymph node involvement, distant metastases as assessed by central readers Secondary Endpoints • Change in intended clinical management • True detection rate • Correct localization rate • Sensitivity • Specificity • Positive Predictive Value • Negative Predictive Value • Safety Study Objective: Determine whether PYLARIFY PSMA PET imaging can detect the presence or absence of additional prostate cancer lesions in patients with FIR prostate cancer, as well as how it may change the patient’s intended management (NCT06074510) See appendix for definition of abbreviated terms.

Page 15

15© 2025 Lantheus. All rights reserved.1. DRG Real World Data (RWD) report; 2. Internal analyses and data on file. 15 FY 2024 4Q 2024 $317.8M FY 2024 Net Sales +13.6% Growth FY 2024 Year-over-Year $86.2M 4Q 2024 Net Sales +17.9% Growth 4Q 2024 Year-over-Year Used in echocardiography exams for >3.5M patients in 20242 #1 Utilized Ultrasound Enhancing Agent1

Page 16

As the #1 utilized UEA, DEFINITY is the clear standard for patients who present with a suboptimal echocardiogram UNENHANCED DEFINITY to adequate echos 3 CONVERTED90% SICU, surgicalintensivecareunit; UEA, ultrasound enhancing agents. . DEFINITY improved cardiac diagnosis and streamlined patient management1-3 33% of patients avoided additional diagnostic procedures3,4 36% of patients experienced a significant change in medical management, procedures, or both3,4 >50% of SICU patients avoided additional diagnostic procedures3,4 References: 1. Data on file, Lantheus. 2. DEFINITY. Prescribing Information. Lantheus. 3. Kurt M, Shaikh KA, Peterson L, et al. Impact of contrast echocardiography on evaluation of ventricular function and clinical management in a large prospective cohort. J Am Coll Cardiol. 2009;53(9):802-810. doi:10.1016/j.jacc.2009.01.005. 4. Results from a prospective study of the impact of UEAs on cardiac diagnoses in 632 patients with technically difficult echocardiograms. of suboptimal echos 20© 2025 Lantheus. All rights reserved.

Page 17

17 U.S. Ultrasound Enhancing Agent TAM is $600M+1 1. U.S. market; Internal Lantheus estimate. 2. Source: AMR, Echocardiography Monthly Monitor and Real World Data; Kurt M et al. Journal of the American College of Cardiology, March 2009; Senior R et al., The European Society of Cardiology, 2006. ©2020 Millennium Research Group, Inc. All rights reserved. Reproduction, distribution, transmission or publication is prohibited. Reprinted with permission. 3. 20%-30% of echocardiograms result in sub-optimal images. Sources: i. Kurt M et al. Impact of contrast echocardiography on evaluation of ventricular function and clinical management in a large prospective cohort. Journal of the American College of Cardiology, Vol 53, No 9, March 2009, 802-810; ii. Platts DG and Fraser JF. Contrast echocardiography in critical care: echoes of the future? A review of the role of microsphere contrast echocardiography. Critical Care and Resuscitation, Vol 12, No 1, March 2011, 44-55; iii. Senior R et al. Clinical benefits of contrast-enhanced echocardiography during rest and stress examinations. The European Society of Cardiology 6, Suppl. 2, 2005, S6-S13. 4. Internal Lantheus estimate. U.S. Echo Market # of Annual Scans 27M-32M Echoes performed in the U.S. annually2 20%-30% or 5M-10M are considered suboptimal 3 U.S. UEA Market ($M) $600M+ U.S. TAM4 U.S. total addressable market Current U.S. UEA Market Size U.S. DEFINITY Sales DEFINITY #1 utilized UEA in the U.S. ~$350M4 Existing Market (FY 2024) © 2025 Lantheus. All rights reserved. Significant Opportunity Remains in the Suboptimal Echo Market

Page 18

Page 19

© 2025 Lantheus. All rights reserved. 19 Innovation that Makes an Impact Includes Pipeline Assets of Life Molecular Imaging and Evergreen Theragnostics* DiagnosticLantheus Diagnostic Therapeutic Pre-Clinical Phase I Phase II Phase III Reg. FilingCandidate Target Isotope Indication/Disease Area Neuro-Endocrine Tumors PNT20031 SSTR2 177Lu GEP-NETs Octevy SSTR2 68Ga GEP-NETs Other Solid Tumors LNTH-1363S FAP 64Cu Tumor/Fibrosis assessment LNTH-2403 LRRC15 Undisc. Solid Tumors LNTH-2404 TROP2 Undisc. Solid Tumors EVG321 CCK2R 177Lu/68Ga SCLC EVG332 MUC16 177Lu/68Ga Solid Tumors EVG341 OXTR 177Lu/68Ga Solid Tumors EVG311 NLGN3 177Lu/68Ga Solid Tumors Neurology / Other MK-6240 (florquinitau) Tau 18F Tau Imaging NAV-4694 (flutafuranol) ß amyloid 18F ß Amyloid Imaging DED MAO-B 18F Neuroimaging Florbetaben ß amyloid 18F Cardiac Amyloid Imaging PI-2620 Tau 18F Tau Imaging GP-1 GPIIB-IIIA 18F Thromboembolism LNTH-24012 GRPR 68Ga Metastatic Prostate CancerProstate Cancer LNTH-24023 GRPR 177Lu Metastatic Prostate Cancer PNT20021 PSMA 177Lu Metastatic Prostate Cancer See Appendix for definition of abbreviated terms *Pipeline includes assets from Life Molecular Imaging and Evergreen Theragnostics. These assets are not currently owned or controlled by Lantheus. The acquisitions are subject to the closing of the transactions, both of which are anticipated to close 2H 2025. 1. Collaboration with POINT Biopharma Global Inc. 2. Also known as 68Ga-RM2 3. Also known as 177Lu-RM2 Therapeutic Evergreen* LMI* Diagnostic Therapeutic

Page 20

20 PNT2003: Somatostatin Receptor (SSTR)–Targeted Radiotherapeutic 1. Based on the most recent update to the FDA’s online paragraph IV database listings. 2. Subject to FDA approval and positive resolution of an ongoing Hatch-Waxman litigation. 3. Factors Influencing Market Potential: Overall increase in epi population, expanding guidelines, and increased utilization of RLT within relevant patient populations. 4. Pheochromocytoma (Pheo) and Paraganglioma (Para) © 2025 Lantheus. All rights reserved. Potential therapeutic agent for the treatment of SSTR-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut and hindgut neuroendocrine tumors in adults FDA accepted Abbreviated New Drug Application (ANDA) – first to file1 Anticipated to be a radioequivalent to LUTATHERA ® (Lutetium Lu 177 Dotatate) Potential launch in 20262 Lung-NETsMetastatic 1L GEP-NETsMetastatic 2L+ GEP-NETs Pheo/Para4 U.S. GEP-NET Radiotherapeutic Market Annual Market Potential3 4,600 5,700 2,500 ~24K Patients ~$6.5B MARKET POTENTIAL ~$1.1B MARKET POTENTIAL ~5K Patients 2025 5,000 6,000 2030 12,000 3,000 3,000

Page 21

21 The Expanding Role of Radiodiagnostics in Alzheimer’s Disease 1. Addressable market based on current management estimates, internal data, and current WAC / 340B pricing.; 2.. Jack CR, et al. Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup. Alzheimer's Dement. 2024; 20: 5143–5169; 3. Rabinovici GD, et.al. Updated appropriate use criteria for amyloid and tau PET: A report from the Alzheimer's Association and Society for Nuclear Medicine and Molecular Imaging Workgroup. Alzheimers Dement. 2025 Jan;21(1):e14338. Epub 2025 Jan 8.; 4. Vermeiren MR, et.al. Survey among experts on the future role of tau-PET in clinical practice and trials. Alzheimers Dement (Amst). 2024 Nov 22;16(4):e70033. © 2025 Lantheus. All rights reserved. 90% of ~300 dementia experts surveyed project Tau PET to add value to clinical practice 4 Advancing the Diagnosis of Alzheimer’s Disease: Detection, Staging, and Monitoring Alzheimer’s Disease PET Imaging Annual Market & Scan Potential ~$1.5B1 ~50K ~300K ~80K 2030 SCREENING STAGING MONITORING recently updated their guidelines2,3 to expand the appropriate use for both β Amyloid and Tau PET imaging

Page 22

18F-MK-6240 is a potential second-generation tau radioligand investigational PET imaging agent without appreciable off-target binding in multiple brain structures 18F-MK-6240 22 MK-6240: Tau © 2025 Lantheus. All rights reserved. DIFFERENTIATED VALUE PROPOSITION ANTICIPATED2,3 HIGH-LEVEL TIMELINES EVIDENCE FOR TARGET VALIDATION2,3DIFFERENTIATING FEATURES ANTICIPATED1 INDICATION ISOTOPE IND-ENABLING PHASE 1 PHASE 2 PHASE 3 NOTES Alzheimer’s Disease 18F NDA filing expected in 2025 Aid in diagnosing and staging as well as monitoring treatment progress and making informed decisions regarding the continuation or discontinuation of therapy High affinity and selectivity for AD/MCI vs non-AD Tau is a protein that helps stabilize the internal skeleton of neurons; in Alzheimer’s disease (AD) specifically, a build up of an irregular form of tau causes this internal skeleton to disassemble Neurofibrillary tau is a pathological hallmark of AD and the extent of deposition in brain correlates with clinical severity In human AD brains, tau is three to four-fold more hyperphosphorylated than the normal adult brain tau MK-6240 binding is elevated in AD patients, and simplified measures such as standardized uptake value ratio (SUVR) correlate with results from kinetic modeling 1. Gogola et al., 2022; 2. Kreisl et al., 2018; 3. Tabeshmehr, P., & Eftekharpour, E., 2023 MK-6240 was more specific and elicited less off- target binding compared to a first-generation tracer Compared to Tauvid 18F-MK-6240 had an approximately 2-fold greater dynamic range in PET signal due to its higher affinity to tau PRODUCT DESCRIPTION & MECHANISM OF ACTION the image shown is only a portion of the full image included as the visual abstract in the publication

Page 23

© 2025 Lantheus. All rights reserved. 23 MK-6240: Widespread Use as a Diagnostic Research Tool Protein Specificity Treatment Modality # of Studies Totals Tau Small Molecule 1 9Antibody 6 ASO 2 β Amyloid Small Molecule 1 8Antibody 5 AAV or siRNA 2 Other Biomarker/Obs 1 3 Antibody 2 Phase 1 Janssen REGISTRY ALZ0001 Novartis CNIO752B12201 Voyager Phase 1/2 Eisai E2814 Lexeo LX1001-02 Phase 2 Alector/AL002-02 & LTE AbbVie M22-721 Biogen/CELIA BMS/CN008-0003 Janssen/Tau Active GSK Progress-AD 219867 Janssen/ALZ2002 Acumen Merck Phase 3 AgeneBio Biogen EMARK Roche Eisai(AHEAD) Eisai/Clarity AD MK-6240 STUDY BREAKDOWN Pharmaceutical companies in partnership 15 Research institutions in collaboration 37 Academia/Research Institution that has more than one clinical trials 103 Studies 45% 40% 15% Other Β Amyloid Tau Completed/Not Active

Page 24

© 2025 Lantheus. All rights reserved. 24 Lussier FZ, Povala G, Bauer‐Negrini G, et al. Longitudinal multicenter head‐to‐head harmonization of tau‐PET tracers: an overview of the HEAD study cohort. Alzheimers Dement. 2025;20(Suppl 9):e094013. Published 2025 Jan 9. doi:10.1002/alz.094013

Page 25

Page 26

NAV-4694 is a potential best-in-class 18F-radiolabeled ß amyloid investigational PET imaging agent for AD diagnosis and patient selection for therapy 18F-NAV-4694 - flutaforanol PRODUCT DESCRIPTION 26 NAV-4694 (flutafuranol): ß amyloid © 2025 Lantheus. All rights reserved. 1. Data on file; 2. Rowe et all., 2016; 3. Ma et al., 2022; 4. Krishnadas et al., 2021 Highest conformance to the gold standard, Pittsburgh Compound B, among 18F β-amyloid imaging agents Detected lower levels of cortical β-amyloid in earlier stages of AD, via lower non-specific white matter binding, improved dynamic range, and improved signal-to-noise ratio vs. first generation tracers HIGH-LEVEL TIMELINES INDICATION ISOTOPE IND-ENABLING PHASE 1 PHASE 2 PHASE 3 NOTES Alzheimer’s Disease 18F NDA filing expected in 2026 DIFFERENTIATING FEATURES ANTICIPATED1,2,4 EVIDENCE FOR TARGET VALIDATION1,3 ß amyloid is an extensively researched protein and is commonly assumed to be a central biological feature of AD, making it a promising target for treatment It is strongly believed that the accumulation of toxic ß amyloid in the central nervous system is the main cause of AD DIFFERENTIATED VALUE PROPOSITION ANTICIPATED Synergetic offering with MK-6240 as the AD-modifying therapeutic market expands Recent approvals of disease-modifying therapies requiring β-amyloid for patient selection and the removal of CMS' restriction on reimbursement are expected to significantly increase demand Offers the potential for earlier diagnosis of AD, increasing the ability to identify patients earlier for therapy 18

Page 27

27 NAV-4694 (flutafuranol): β Amyloid Performance Characteristics SUPERIOR GREY MATTER/ WHITE MATTER SIGNAL RATIO AND DYNAMIC RANGE5 HIGHEST CONFORMANCE TO THE GOLD STANDARD1,3 Pittsburgh Compound B (C11 PIB) is the index compound for centiloid scaling, the tool used to enable comparison of β amyloid imaging across tracers The centiloid scale anchors at 0 to normal expression of β amyloid at the low end and extends to characterize high amyloid burden at 100 Due to these properties, NAV-4694 generates high contrast images that are easy to interpret by visual read and the ability to detect low levels of β-amyloid pathology with high accuracy NAV-4694 demonstrated the greatest conformance to C11 PIB among F18 ß amyloid imaging agents with the least variance across the spectrum of patients from young controls to extensive disease NAV-4694 showed notably lower variance compared to Amyvid, Vizamyl and Neuraceq NAV-4694 closely aligns to C11 PIB across the scale TABLE 1 CENTILOID CONVERSION EQUATIONS FOR COMMONLY-USED F18 ß AMYLOID TRACERS2 Gray Matter/White Matter Signal Ratio Flutafuranol Amyvid Vizamyl Neuraceq SUVR Ratio (GM/WM) A Dynamic Range Flutafuranol Amyvid Vizamyl Neuraceq Dynamic Range relative to PIB B Source: 1. Rowe CC, et al. J Nucl Med. 2016;57(8):1233-1237; 2. Krishnadas et al. Seminars in Nuclear Medicine, Volume 51, Issue 3, 2021,Pages 241 -252; 3. Klunk WE, Koeppe RA, Price JC, et al. The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET. Alzheimers Dement. Jan 2015;11(1):1-15 e1-4. doi:10.1016/j.jalz.2014.07.00; 4. Rowe CC, Dore V, Jones G, et al. (18)F- Florbetaben PET beta-amyloid binding expressed in Centiloids. Eur J Nucl Med Mol Imaging. Nov 2017;44(12):2053-2059. doi:10.1007/s00259-017-3749-6; 5. Navitsky M, Joshi AD, Kennedy I, et al. Standardization of amyloid quantitation with florbetapir standardized uptake value ratios to the Centiloid scale. Alzheimers Dement. Dec 2018;14(12):1565-1571. doi:10.1016/j.jalz.2018.06.1353; 6. Battle MR, Pillay LC, Lowe VJ, et al. Centiloid scaling for quantification of brain amyloid with [(18)F]flutemetamol using multiple processing methods. EJNMMI Res. Dec 5 2018;8(1):107. doi:10.1186/s13550 -018-0456-

Page 28

© 2025 Lantheus. All rights reserved 28 LNTH-2401/2402: GRPR Potential best-in-class opportunity 1. Data on file; 2. Cornelio et al., 2007; Percentages include % positive binding and immunohistochemistry (IHC) scores; 3. Rinne, S.S., Abouzayed, A., Gagnon, K. et al. 66Ga-PET-imaging of GRPR-expression in prostate cancer: production and characterization of [66Ga]Ga-NOTA- PEG2-RM26. Sci Rep 11, 3631 (2021); 4. Ananias, Hildo JK, et al. "Expression of the gastrin‐releasing peptide receptor, the prostate stem cell antigen and the prostate‐specific membrane antigen in lymph node and bone metastases of prostate cancer." The Prostate 69.10 (2009): 1101-1108; 5. Baun et al. 2024, Seminars in Nuclear Medicine Volume 54, Issue 2, March 2024, Pages 256-269; 6. Verhoeven et al., PMC10502172. PRODUCT DESCRIPTION & MECHANISM OF ACTION EVIDENCE FOR TARGET VALIDATION2,3,4,6 GRPR / BBN expression characterized as ranging from 63% - 100% in primary prostate cancer, but minimally expressed in normal tissue; patients may express PSMA and GRPR heterogeneously SUMMARY OF GRPR EXPRESSION IN CANCER HIGH-LEVEL TIMELINE 68Ga / 177Lu-LNTH-2401 LNTH-2401 / LNTH-2402 RM2 is an investigational gastrin- releasing peptide receptor (GRPR) targeted-peptide 17% 33% 35% 38% 50% 56% 73% 76% 77% 88% 100% 0% 25% 50% 75% 100% Pancreatic SCLC Renal Uterine Gastric Breast Neuroblastoma Colon Ovarian Prostate Head & Neck % Positive GRPR Expression2 INDICATION ISOTOPE IND-ENABLING PHASE 1 PHASE 2 NOTES mCRPC 68Ga IND filing expected 4Q 2025 Phase 1 initiation planned 2026 177Lu LNTH-2401 LNTH-2402 Complementary to portfolio and offers potential commercial synergies Unlike PSMA-targeted RLT, where the kidneys are the limiting organ, the pancreas takes more absorption but can tolerate higher radiation doses High density expression in a broad range of other cancers2 DIFFERENTIATED VALUE PROPOSITION ANTICIPATED Potential to target Prostate Cancer patients whose tumor(s) do not express PSMA or are ineligible for PSMA-targeted RLT ~15% - 25% of mCRPC patients have low to no PSMA expression N N N N O H N - OOC COO - - OOC N D-Phe-Gln-Trp-Ala- O 68Ga3+ -Val-Gly-His-Sta-Leu-NH2 N N N N O H N - OOC COO - - OOC N D-Phe-Gln-Trp-Ala- O 68Ga3+ -Val-Gly-His-Sta-Leu-NH2 177Lu3+

Page 29

© 2025 Lantheus. All rights reserved 73-y-old man diagnosed as having prostate cancer (white arrow) with lymph node involvement (red arrow) and bone metastasis (yellow arrow) before prostatectomy. LNTH-2401/2402: GRPR Potential best-in-class opportunity 29 1. Zhang J, Niu G, Fan X, Lang L, Hou G, Chen L, Wu H, Zhu Z, Li F, Chen X. PET Using a GRPR Antagonist68Ga-RM26 in Healthy Volunteers and Prostate Cancer Patients. J Nucl Med. 2018 Jun;59(6):922-928. doi: 10.2967/jnumed.117.198929. Epub 2017 Nov 9. PMID: 29123014; PMCID: PMC6004560. A: 99mTc-MDP bone scintigraphy, B: 68Ga-RM26 PET/CT, C: 68Ga-BBN PET/CT 68Ga-RM26 PET/CT detected primary tumors, multiple lymph node involvement, and bone metastasis lesion, whereas those lesions did not significantly show up on 99mTc-MDP bone scintigraphy and showed extremely mild uptake on 68Ga-BBN PET/CT.1

Page 30

© 2025 Lantheus. All rights reserved 30 LNTH-2403: LRRC15 Potential First-in-Class Therapy in a Range of Solid Tumor Types DIFFERENTIATED VALUE PROPOSITION ANTICIPATED HIGH-LEVEL TIMELINE DUNP19 has unique “dual action,” targeting ability, targeting both tumor cells and the surrounding environment (stroma) LRRC15 is widely expressed across a range of tumors, opening a pan-tumor opportunity for treatment of various cancers Source: Human Protein Atlas. Note: TPM = transcripts per million; IHC = immunohistochemistry. 1. Purcell et al, 2018. 2. Storey et al., 2024. EVIDENCE FOR TARGET VALIDATION2 LRRC15 is highly expressed on cancer-associated fibroblasts (CAFs) within the tumor stroma of a wide range of malignancies, and on cancer cells from a subset of mesenchymal tumors with low expression in normal tissues Expression of LRRC15 is associated with TGF beta driven aggressive malignant disease Studies carried out in various tumor models with LRRC15+ cancer cells and LRRC15+ CAFs have demonstrated that DUNP19 selectively accumulated in LRRC15+ cells after systemic injection and co-localizes with LRRC15 INDICATION IND-ENABLING NOTE Osteosarcoma IND filing expected 4Q 2025 A basket study is currently being planned in additional indications, including 3 different types of cancer. LNTH-2403 DUNP19 is an investigational Leucin Rich Repeat Containing 15 (LRRC15)-targeted, fully humanized, mAb LNTH-2403 is DUNP19 conjugated to radioisotope 177- Lutetium via a DOTA chelator 177Lu-LNTH-2403 0 5 10 15 20 25 Pancreatic Lung-squamous Lung-adeno Head&Neck Breast LRRC15 TPM EXPRESSION IN HEALTHY & MALIGNANT TISSUES 58% 65% 66% 72% 72% 81% 91% 95% 0% 25% 50% 75% 100% Melanoma NSCLC; Squamous Pancreatic NSCLC; Adeno Sarcoma (Mult. Subtypes) Head & Neck TNBC Ductal + Lobular Breast IHC Score (% Positive) PRODUCT DESCRIPTION & MECHANISM OF ACTION SUMMARY OF LRRC15 EXPRESSION IN CANCER1 Tumor Normal

Page 31

PRODUCT DESCRIPTION LNTH-1363S is a novel, investigational FAP-targeted, small molecule compound comprising a FAP binding domain, an albumin-binding domain for PK modulation and a chelator to contain a radionuclide LNTH-1363S can be labeled with Cu-64 or Ga-68 radioisotopes for PET imaging use 64Cu-LNTH-1363S 31 LNTH-1363S: FAP Potential to Replace 18F-FDG Particularly in Brain, Liver, Gastro-Intestinal Cancers © 2025 Lantheus. All rights reserved. DIFFERENTIATED VALUE PROPOSITION ANTICIPATED DEVELOPMENT PLAN FAP is expressed widely across a range of tumor types, opening a very large opportunity for imaging of various cancers FAP-targeted agents may advance detecting and monitoring fibrotic diseases, including liver cirrhosis, pulmonary fibrosis, and cardiac fibrosis, thereby extending their utility beyond oncology Based on imaging studies, low background and high uptake may differentiate LNTH- 1363S from FDG in some tumor types and locations • Imaging studies with 68Ga-FAPI-04 have demonstrated positive uptake in a wide range of tumors Source: Human Protein Atlas; 1. Kratochwil et all., 2019. 2. Liu et all., 2015. Fibroblast Activation Protein Overexpression and Clinical Implications in Solid Tumors: A Meta-Analysis; 3. Mori et al., 2024 MASH: Metabolic Dysfunction-Associated Steatohepatitis; COPD: Chronic Obstructive Pulmonary Disease; CLAD: Chronic lung allograft dysfunction; SUV = Standardized Uptake Value; FPI = First Patient Initiated FAP is expressed in many solid tumors, either in the cancer cells themselves or in the supporting stroma FAP is nearly absent in healthy tissues, but highly upregulated during tissue remodeling in embryogenesis, cancer, and fibrosis In chronic diseases, persistent activation of FAP+ fibroblasts (promoted by TGF-β) leads to excessive extracellular matrix deposition contributing to organ fibrosis in conditions like pulmonary fibrosis, cardiac fibrosis, and liver cirrhosis INDICATION ISOTOPE IND-ENABLING PHASE 1 NOTES Met. Sarcoma 64Cu FPI expected in 2025 Cardiac 64Cu Exploratory collaborative studies in discussion COPD/CLAD 64Cu MASH 68Ga / 64Cu Fibrosis Undisclosed 68Ga-FAPI UPTAKE IN VARIOUS TUMORS1 4 5 6 7 7 7 8 9 10 11 12 13 14 15 18 0 5 10 15 20 Gastric Hepatocellular Cervical Colorectal NETs MTC Ovarian Head & Neck Pancreatic Prostate Lung Breast Esophageal Salivary Gland Sarcoma Average SUVmax EVIDENCE FOR TARGET VALIDATION1,2,3

Page 32

32 * Subject to customary closing conditions. 1. Collaboration with POINT Biopharma Global Inc. 2. Also known as 68Ga-RM2 3. Also known as 177Lu-RM2 Diagnostic Therapeutic © 2025 Lantheus. All rights reserved. Other Solid Tumors Neurology Neuro-Endocrine Tumors Prostate Cancer NAV-4694 (flutafuranol) ß amyloid PNT20021 PSMA Phase 3 LNTH-24012 GRPR Phase 2 PNT20031 SSTR2 Registrational-stage LNTH-1363S FAP Phase 1 MK-6240 (florquinitau) Tau Phase 3 LNTH-24023 GRPR Phase 3 LNTH-2403 LRRC15 LNTH-2404 TROP2 Key 2025 Milestones Advancing our Diversified Portfolio in High Value Markets KEY 2025 MILESTONES PROSTATE CANCER • Non-Prostate PYLARIFY Study Initiated (2Q) • MIRROR Study Enrollment Completion (4Q) • RM2 IND Submission (4Q) GEP-NETs • PNT2003 Tentative ANDA Approval (2025) OTHER SOLID TUMORS • LNTH-1363S First Patient Dosed (2025) • LRRC15 IND Submission (4Q) ALZHEIMER'S DISEASE • MK-6240 NDA Submission (2025) EVERGREEN THERAGNOSTIC CLOSE* 2H 2025 LMI CLOSE* 2H 2025

Page 33

Driven by a Purpose to Improve Patient Outcomes Lantheus continues to advance innovative radiopharmaceuticals and drive scientific and commercial excellence across oncology, neurology and cardiology 33 Deliver on Long-Term Growth and Sustainable Value Creation © 2025 Lantheus. All rights reserved. Powering the Future of Radiopharmaceuticals Strengthen position as a fully integrated radiopharmaceutical leader with enhanced end-to-end expertise and capabilities • Ability to scale production of radiopharmaceuticals • Positioned to accelerate development and lifecycle management through end-to-end supply chain Industry Leadership Augment our resources in innovative radiopharmaceuticals • Long-term and diversified revenue generation enables capital flexibility to invest in pipeline assets Sharpened Strategic Focus Further diversify our diagnostic and therapeutic portfolio with high- potential, complementary assets • Efficient advancement of catalyst-rich pipeline driven by R&D expertise Portfolio Diversification

Page 34

Page 35

© 2025 Lantheus. All rights reserved. 35 (a) The income tax effect of the adjustments between GAAP net income and adjusted net income (non-GAAP) takes into account the tax treatment and related tax rate that apply to each adjustment in the applicable tax jurisdiction. Reconciliation of GAAP to Non-GAAP Financial Measures (in thousands, except per share data – unaudited)

Page 36

Page 37

Management Team Led by Proven Pharmaceutical Industry Veterans 37 Driven by a purpose to improve patient outcomes, Lantheus' experienced leadership team brings decades of expertise in advancing innovative radiopharmaceuticals and driving scientific and commercial excellence in everything we do Previous Experience Paul Blanchfield President Bob Marshall CFO and Treasurer Brian Markison CEO Amanda Morgan Chief Commercial Officer Jamie Spaeth Chief People Officer Daniel Niedzwiecki Chief Administrative Officer Jean-Claude Provost, MD Chief Science Officer © 2025 Lantheus. All rights reserved.

Page 38

Strategy Guided by Experienced, Engaged Board of Directors 38 Board of seasoned leaders with extensive expertise across healthcare, finance, and business management, supporting Lantheus’ ability to shape the future in delivering innovative diagnostic and therapeutic solutions Julie McHugh Director Dr. Phuong Khanh (P.K.) Morrow Director Heinz Mäusli Director Gary Pruden Director James Thrall Director Mary Anne Heino Chairperson of the Board Brian Markison Director Minnie Baylor-Henry Director Gérard Ber Director Julie Eastland Director Samuel Leno Director © 2025 Lantheus. All rights reserved.

Page 39

© 2025 Lantheus. All rights reserved. 39 Radiopharmaceutical Leader Ready to Strengthen Capabilities at Forefront of Innovation and Patient Care Pioneer with history spanning over 65 years of leadership in radiopharmaceuticals to positioning Lantheus to champion the future of this increasingly Important scientific field. Advanced R&D engine positioned to generate steady pipeline of diagnostics and therapeutics that provide meaningful clinical outcomes. Proven success of flagship diagnostic agents with PYLARIFY the #1 utilized PSMA PET imaging agent that reached blockbuster status in 2024 with $1B+ in sales and DEFINITY – #1 ultrasound enhancing agent used in U.S. for 20+ years. Purpose-built market- leading operations, including advanced research, clinical and commercial manufacturing capabilities, position Lantheus as the premier, one-stop-shop to address the complex demands of radiopharmaceutical discovery, development and production. Geographically diverse with multi-channel PMF network, supporting sustained supply, reliability and treatment logistics for real-time delivery, and strong international infrastructure, commercial footprint able to enable growth in attractive global markets. Powered by our industry expertise, growing pipeline, and proven manufacturing and commercial platform, we are launching Lantheus’ next phase of growth Subject to closing of recently announced transactions

Page 40

© 2025 Lantheus. All rights reserved. 4040 40 Utilized PSMA PET Imaging Agent1 PYLARIFY is a radioactive diagnostic agent indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer • with suspected metastasis who are candidates for initial definitive therapy • with suspected recurrence based on elevated serum prostate-specific antigen (PSA) level 2 1. Internal analyses and data on file; 2. PYLARIFY® [package insert]. North Billerica, MA: Progenics Pharmaceuticals, Inc., a Lantheus company

Page 41

© 2025 Lantheus. All rights reserved. 41 1. Market research interviews, survey, and analysis, Wenzel 2021 Prostate, Nezolosky 2018 J. Clin. Oncol., Agrawal 2020 JAMA. 2. Scher HI, Solo K, Valant J, Todd MB, Mehra M. 2015. Prevalence of Prostate Cancer Clinical States and Mortality in the United States: Estimates Using a Dynamic Progression Model. PloS one 10: e0139440. Based on: CDC.gov, SEER Database, NCCN.org and Axiom Primary and Secondary Market Research and Analysis, validated by Bohm Epidemiology 2020. 3. Global Data 3rd line treatment for metastatic castration-resistant prostate cancer (“mCRPC”), Lantheus primary market research informing imaging procedures performed during radioligand treatment. 4. Lantheus market research and analysis with ordering physicians, NCCN, ACS, UpToDate, SEER. Prostate Cancer Patients May Undergo Imaging Several Times During Their Disease Journey Recurrent Disease (RD) 3-5 YEARS 1-10 YEARS 1-3 MONTHS Illustrative Pt. with Local OR Locoregional Disease PCa Negative PCa Positive Initial Evaluation for Prostate Biopsy Intermediate Unfavorable, High or Very High Risk Active Surveillance (low risk) Active Treatment (medium/high risk) Screening (PSA +/- DRE) Establish presence of metastatic disease Monitoring for disease progression Treatment for oligo- metastatic disease Treatment for metastatic disease Response evaluation without imaging Response evaluation with imaging Treatment for non- metastatic disease Definitive Treatment +/- ADT ~330K Patients2 ~145K Patients1 Treatment for oligo- metastatic disease Treatment for metastatic disease Response evaluation without imaging Response evaluation with imaging Treatment for non- metastatic disease Monitoring for disease progression Establish presence of metastatic disease ~30K Patients2 ~20K Patients3 3L mCRPC BCR Recurrence Estimated 2-3% annual growth due to increasing incidence / prevalence4 Initial Staging Radioligand Therapy # Annual IncidencePSMA PET Imaging Current Addressable U.S. Market is ~445K Annual Scans or $2B+

Page 42

PYLARIFY Manufacturing Supported by Sizeable U.S. PMF Network – U.S. cyclotron network already supports 2+ million FDG doses on an annual basis 42 Geographically Diverse, Multi-Channel PMF Network Provides Sustained Supply and Reliability PMF = PET Manufacturing Facility. 1. IMV 2022 PET Imaging Market Summary Report; 2.Data on file. © 2025 Lantheus. All rights reserved. PYLARIFY DELIVERS Best-in-Class Patient & Customer Experience Continue to expand our manufacturing capacity to ensure PSMA PET with PYLARIFY is the imaging agent of choice in prostate cancer Working with our manufacturing partners to expand delivery windows Additional PMFs provide geographic breadth, out-the-door time flexibility and added optionality to our existing network PMF partners include both commercial and academic partners Operational enhancements, such as adding additional synthesis boxes, enable us to serve customers “on-time-in-full” at a rate of 98%+ Demonstrates our operational excellence that we strive to deliver to all our customers 90%+ of covered lives have access to PYLARIFY2 Significant Capacity per PMF PMFs have already demonstrated the ability to produce: Some PMFs producing: 3 batches per day; 5 days per week 40+ PYLARIFY doses per batch Contracted with 100% of our targeted academic centers2 PYLARIFY CAPACITY ENHANCEMENTS Additional PMFs Additional Cyclotrons Additional Synthesis Boxes Improved Efficiency Increased Cyclotron Time

Page 43

Leading U.S. Ultrasound Enhancing Agent2 © 2025 Lantheus. All rights reserved. 43 Indicated for use in adult and pediatric patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border 1 1. DEFINITY® [package insert]. North Billerica, MA; 2.. Internal analyses and data on file;.

Page 44

44 DEFINITY® is the #1 Utilized Ultrasound Enhancing Agent in the U.S.1 1. Data on file, Lantheus. 2. DEFINITY® [package insert]. N. Billerica, MA: Lantheus, Inc. © 2025 Lantheus. All rights reserved. DEFINITY® (Perflutren Lipid Microsphere) is a diagnostic ultrasound enhancing contrast agent used to opacify the left ventricular chamber and to improves the delineation of the left ventricular endocardial border in adult and pediatric patients with suboptimal echocardiograms.2 IN THE U.S. contrast-enhanced echoes are performed with DEFINITY® MORE THAN 21 million studies performed OUT OF4 5 DEFINITY® HAS BEEN INCLUDED IN MORE THAN 3200 peer-reviewed publications DEFINITY® is a trusted UEA with more than 20 years in the market

Page 45

45 DEFINITY® Reduced the Need for Additional Cardiac Imaging and Decreased the Length of a Hospital Stay1 1. Kurt M, Shaikh KA, Peterson L, et al. Impact of contrast echocardiography on evaluation of ventricular function and clinical management in a large prospective cohort. J Am Coll Cardiol. 2009;53(9):802-810. © 2025 Lantheus. All rights reserved. DEFINITY® converted 90% of suboptimal echocardiogramsto adequate studies 33% of patients avoided additional diagnostic procedures 36% of patients experienced a significant change in medical management avoiding additional, procedures or both 90% 36%33%

Page 46

46 Glossary of Terms AAV: Adeno-associated virus AD: Alzheimer’s Disease AE: adverse event ANDA: Abbreviated New Drug Application BCR: biochemical recurrence CCK2R: cholecystokinin-2 receptor CLR: correct location rate EPS: earnings per share FAP: Fibroblast activation protein FDA: Food and Drug Administration GEP-NET: Gastroenteropancreatic neuroendocrine tumors GPIB-IIIA: Glycoprotein IIb/IIIa GRPR: Gastrin-releasing peptide receptor ISUP: International Society of Urological Pathology LRRC15: Leucine-Rich Repeat- Containing Protein 15 MAO-B: Monoamine oxidase B mHSPC: metastatic hormone- sensitive prostate cancer MCI: mild cognitive impairment mCRPC: metastatic castration- resistant prostrate cancer MUC16: mucin 16 NLGN3: Neuroligin 3 NPV: negative predictive value OXTR: oxytocin receptor PC: prostate cancer PET: positron emission tomography PLND: pelvic lymph node dissection PMF: PET Manufacturing Facility PPV: positive predictive value PSMA: Prostate specific membrane antigen R/P: radical prostatectomy siRNA: Small interfering Ribonucleic acid SSTR: Somatostatin receptor SUVR: Standardized Uptake Value Ratio TAM: total addressable market TROP2: Trophoblast cell surface antigen-2 UEA: ultrasound enhancing agent © 2025 Lantheus. All rights reserved.

Slides